IsoRay, Inc. (AMEX: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced it will host a booth at the 80th Annual Meeting of the American Association of Neurological Surgeons (AANS). The annual meeting will take place April 14-18, 2012 in Miami Beach, Florida at the Miami Beach Convention Center.
IsoRay’s participation marks the Company's formal introduction to the neuroscience community. At IsoRay’s booth (Booth 952), a series of discussion groups and presentations will be taking place led by a number of thought leaders from major medical centers. In addition to demonstrating the GliaSite® radiation system, the booth will also feature slide shows, videos, and working demonstrations of the application of mesh with embedded seeds.
IsoRay has exclusive worldwide distribution rights for the GliaSite® radiation therapy system. GliaSite® is an innovative, significant advance over previous brain cancer treatments. Doctors are able to use the system to directly place a specified dosage of liquid radiation in areas where cancer is most likely to still remain after completion of surgical brain tumor removal. The ability to precisely place a specified dosage of this form of radiation means there is less likelihood for damage to occur to healthy brain tissue compared to other alternative treatments. Importantly, the GliaSite® radiation treatment impacts the ability of the tumor to recur which means crucial benefits for patients in longevity as well as quality of life.
In another key development, yet another leading institution has adopted the GliaSite® radiation therapy system. The University of Maryland has just completed its first treatment of a brain cancer patient using GliaSite®. According to IsoRay CEO Dwight Babcock some 65,000 new cases of primary brain tumors are expected to be diagnosed this year amongst all age groups. "Brain cancer doesn't discriminate. It afflicts men, women, and children with devastating impact. GliaSite® is showing dramatic results in treating a variety of brain cancers and we are confident that physicians will quickly adopt this vital treatment."